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Abstract
Introduction Little is known about the natural course of
renal function and renal hemodynamics in heart failure
patients with reduced ejection fraction (HFREF).
Methods and results We prospectively studied effective
renal plasma flow (ERPF) and glomerular filtration rate
(GFR) in 73 HFREF patients with 125I-iothalamate/131I-
hippuran clearances with a mean follow-up of
34.6 ± 4.4 months. Fifteen percent were female, with age
58 ± 12 years and left ventricular ejection fraction
(LVEF) 29 ± 10 %. Baseline GFR was 81 ± 23 mL/min/
1.73 m2 and declined 0.6 ± 4.7 mL/min/1.73 m2 per year.
Baseline ERPF was 292 ± 83 mL/min/1.73 m2 and
declined 4.3 ± 19 mL/min/1.73 m2 per year. Of the base-
line variables, older age and high urinary kidney injury
molecule-1 were the only variables associated with GFR
decline (p\ 0.05). Following stepwise backward analysis,
only age (p\ 0.001) remained significant. In addition, we
found an association between change in GFR and changes
in ERPF, N-terminal pro-brain natriuretic peptide and
renovascular resistance. In the multivariable analysis, only
the change in ERPF remained significantly associated with
a change in GFR (p\ 0.001).
Conclusion In this cohort of stable chronic HFREF
patients, the average decline in GFR over time was small.
The decline of GFR was associated with a higher age and a
lower baseline GFR, and was strongly related to changes in
renal perfusion.
Keywords Cardiorenal  Heart failure  Renal blood
flow  Kidney  Biomarkers
Introduction
Both chronic kidney disease (CKD) and worsening renal
function are common in heart failure patients [1–3] and
among the most powerful predictors of morbidity and
mortality in this population [4]. However, little is known
about the natural course of renal function in heart failure
patients and determinants of long-term renal function
decline. The cause of renal dysfunction in HFREF is
thought to be multifactorial [5, 6]. It has been attributed to
medication [7], renin–angiotensin–aldosterone system
(RAAS) activation [8], sympathetic nervous system (SNS)
activation and inflammation. Decreased renal perfusion is
likely the key determinant [9], via decreased renal perfu-
sion pressure, an increase in renovascular resistance
(RVR), increase in renal venous pressure or all of the above
[10]. However, these associations have mostly been
described in cross-sectional studies. The limited number of
longitudinal studies has mostly focused on acute worsening
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of renal function, and few data are available on predictors
of long-term estimated glomerular filtration rate (GFR)
changes in heart failure patients with reduced ejection
fraction (HFREF) [11–14]. All these studies used changes
in serum creatinine to estimate GFR, which is considered a
surrogate for the functioning kidney tissue. However, cre-
atinine-based renal function estimates are not always
accurate in estimating kidney function decline [15] and
provide no information on renal hemodynamics.
Using gold standard techniques for measuring renal
function, we studied the change in renal function over time
and its clinical, biochemical and hemodynamic predictors
in patients with heart failure. We previously described the
cross-sectional associations. Renal blood flow showed the
strongest association with GFR. In turn, N-terminal pro-
brain natriuretic peptide (NT-proBNP), plasma renin
activity, soluble vascular cell adhesion molecule-1
(sVCAM-1) levels and urinary albumin excretion (UAE)
showed the strongest associations with renal blood flow
[9]. In the current analysis, we investigated if these
parameters are also associated with long-term renal func-




Details on the study design and patient population have
been published previously [9]. In brief, 120 clinically
stable HFREF patients, with left ventricular ejection frac-
tion (LVEF)\45 % and stable heart failure medication for
at least 1 month underwent renal function measurements
using 125I-iothalamate and 131I-hippuran clearance tech-
niques at the University Medical Center Groningen, The
Netherlands. Blood and urine samples were collected, a
physical examination performed and the patient’s history
documented. Patients were contacted after 3 years and all
investigations were repeated. The study was approved by
the ethics committee of the study center, and all subjects
gave written informed consent. The study was conducted in
accordance with Declaration of Helsinki guidelines.
Renal and cardiac function measurements
Renal function measurements were performed using
radioactive labeled tracers, 125I-iothalamate and 131I-hip-
puran, as described previously [16]. This method has an
intra- and inter-test variation of 1.9 and 2.9 %, respec-
tively, for GFR. The intra-subject day-to-day CV of
effective renal plasma flow (ERPF) is 5.0 % [17]. The
filtration fraction was calculated as GFR/ERPF. RVR was
calculated as (mean arterial pressure/ERPF) 9 (1 - he-
matocrit) and expressed in mmHg/mL/min. GFR and ERPF
were corrected for 1.73 m2 of body surface area, calculated
using the Dubois formula. LVEF was determined by
nuclear ventriculography.
Laboratory methods
Patients were all in the supine position during renal
measurements, and a venous blood sample was drawn 2 h
after the start of the measurements. Routine hematology,
blood chemistry and urinalysis were performed within an
hour of collection. Additional blood and urine samples
were immediately centrifuged and stored at -80 C.
Urinary markers of renal damage were measured in 24 h
urine collections and corrected for urinary creatinine as
described previously [18]. A detailed description of the
methods and analytical variation is provided in supple-
ment 1.
Follow-up
All patients were asked to return for a follow-up visit
between 24 and 36 months after baseline renal function
measurements. All measurements performed at baseline
were repeated including laboratory analyses, renal function
measurements using radioactive labeled tracers and nuclear
ventriculography. Adverse events during follow-up were
determined via interview and case record extraction.
Adverse events included death from any cause, heart
transplantation, cardiovascular event (myocardial infarc-
tion or primary percutaneous coronary intervention or
primary coronary artery bypass grafting) and first hospi-
talization for worsening heart failure.
Statistical analyses
Continuous data are presented as mean ± standard devia-
tion (SD) when normally distributed, as median and inter-
quartile range when non-normally distributed and as fre-
quencies and percentages for categorical variables. Dif-
ferences between groups were tested using Student’s T test,
Kruskal–Wallis or Chi-square test as appropriate. Linear
regression analysis was carried out to determine the asso-
ciation of baseline variables with change in GFR and to test
the association of changes in hemodynamic parameters
with changes in GFR. Linear regression models with delta
variables were corrected for baseline values of the vari-
ables of interest. Age and sex were included in all multi-
variable models. Skewed variables were log-transformed
where appropriate. Variables associated with the univari-
able model at p\ 0.1 were included in a stepwise, back-
ward multivariable regression analysis, with a threshold for
Clin Res Cardiol (2016) 105:10–16 11
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variable retention of p\ 0.1. All reported probability
values are two tailed, and a p value of\0.05 was consid-
ered to be statistically significant. Statistical analyses were
performed and graphics created using STATA version
11.0, College Station, TX, USA.
Results
Of the 120 patients included at baseline, 73 returned for
follow-up measurements (Fig. 1). The baseline character-
istics of the study population are presented in Table 1. In
brief, 15 % were female, with a mean age of
58 ± 12 years. The left ventricular ejection fraction
(LVEF) was 29 ± 10 %. Most patients had New York
Heart Association (NYHA) class II or III heart failure
symptoms. All patients were on an angiotensin-converting
enzyme inhibitor and/or angiotensin receptor blocker and
most were on beta-blocker therapy or aldosterone receptor
antagonists.
Baseline GFR was 81 ± 23 mL/min/1.73 m2 and base-
line ERPF was 292 ± 83 mL/min/1.73 m2. The mean
follow-up time was 34.6 ± 4.4 months. In patients with a
complete follow-up, the mean decline in GFR was
0.6 ± 4.7 ml/min/1.73 m2 per year and ERPF declined
4.3 ± 19 mL/min/1.73 m2 per year. There was no signifi-
cant difference in the rate of renal function decline between
patients with a GFR below and above 60 mL/min/1.73 m2
at baseline (p = 0.81). Patients who were lost to follow-up
are also presented in Table 1. Patient who died or had a
heart transplant during follow-up had a lower blood pres-
sure, GFR, ERPF and filtration fraction, and a higher RVR,
UAE and NT-proBNP and were more often using angio-
tensin receptor blockers (ARB) or aldosterone receptor
antagonists (ARA) compared with patients who completed
follow-up. There were no significant differences between
patients who completed follow-up and those who were lost
to follow-up for other reasons.
Predictors of changes in GFR
Baseline variables
Associations of baseline characteristics and laboratory tests
with change in GFR are shown in Table 2. Baseline age,
sex, mean arterial pressure, neutrophil gelatinase-associ-
ated lipocalin (NGAL) and kidney injury molecule 1
(KIM-1) showed a relation with change in GFR at p\ 0.1
(Table 2). Following stepwise backward analysis, only
older age (p\ 0.001) remained significantly associated
with higher GFR decline in a multivariable model.
Changes in hemodynamics and renal perfusion
In general, patients who completed follow-up maintained a
relatively stable hemodynamic profile. Changes in LVEF
(?3.3 ± 11 %), mean arterial pressure
(-0.13 ± 10 mmHg), NT-proBNP [-0.6 (-265 to
?250.6)ng/L] and RVR (0.01 ± 0.05 mmHg/mL/min)
were modest. A decrease in ERPF and NT-proBNP and
increase in RVR were associated with a decrease in GFR,
while LVEF was not (Table 3; Fig. 2). In the multivariable
analysis, only change in ERPF remained significantly
associated with a change in GFR. In parallel to changes in
GFR, an increase in RVR and a decrease in NT-proBNP
and LVEF were associated with a decrease in ERPF. In
multivariable analysis, only RVR and NT-proBNP
remained significantly associated with changes in ERPF
(results not shown). Change in mean arterial pressure was
not associated with a change in either GFR or ERPF.
Discussion
In the present study of patients with stable HFREF, we
found only a small decrease in GFR over a longer period of
time, in the order of magnitude also reported as the age-
related decline in the general population. Likewise, ERPF
decline did not differ much from the age-related decline
rate in the general population [19]. Change in GFR was
strongly associated with a parallel change in ERPF. Only
higher age and lower baseline GFR predicted a greater
decline in GFR over time, but none of the tested urinary
biomarkers of renal damage or hemodynamic parameters
were associated with GFR decline.
Several studies have focused on markers predicting
worsening renal function in chronic heart failure, with
limited success. The identified risk factors include con-
gestion [20], vascular disease, diuretics, advanced age, left
ventricular ejection fraction and worse renal function at
baseline [4, 7, 11]. Furthermore, NGAL and NT-proBNP
have been linked to worsening renal function in acute heartFig. 1 Patient disposition




Variable With follow-up Lost to follow-up Died/HTX
(n = 73) (n = 25) (n = 22)
Age (years) 58 ± 12 58 ± 12 62 ± 12
Female sex, n (%) 11 (15 %) 7 (28 %) 6 (27 %)
RR systolic (mmHg) 121 ± 18 127 ± 21 105 ± 20#
RR diastolic (mmHg) 71 ± 11 70 ± 11.2 62 ± 11#
Heart rate (bpm) 64 ± 12 66 ± 12 68 ± 16
Ischemic etiology, n (%) 39 (53 %) 11 (44 %) 10 (46 %)
LVEF (%) 29 ± 10 30 ± 10 28 ± 10
GFR (mL/min/1.73 m2) 81 ± 23 75 ± 28 50 ± 26#
ERPF (mL/min/1.73 m2) 292 ± 83 264 ± 90 202 ± 73#
Filtration fraction (%) 28 ± 3 28 ± 6 24 ± 8#
RVR (mmHg/mL/min)* 0.17 (0.15–0.22) 0.19 (0.14–0.29) 0.22 (0.18–0.31)#
UAE (mg/24 h)* 8 (6–12) 12 (7–35) 18 (7–49)#
NT-proBNP (ng/mL)* 465 (219–1100) 635 (286–1700) 2200 (950–5000)#
Urine NGAL (lg/24 h)* 15 (7–31) 17 (11–34) 9 (2–33)
Urine KIM-1 (U/24 h)* 408 (144–995) 416 (111–1800) 279 (20–1100)
Urine NAG (ng/24 h)* 4.4 (2.2–6.6) 3.7 (2.5–7.9) 3.4 (2.4–7.5)
ACE inhibitor, n (%) 65 (89 %) 21 (84 %) 16 (73 %)
ARB, n (%) 8 (11 %) 3 (12 %) 7 (32 %)**
Beta-blocker, n (%) 63 (86 %) 20 (80 %) 18 (82 %)
Aldosterone antagonist, n (%) 18 (25 %) 6 (24 %) 13 (59 %)#
Normally distributed data are presented as mean ± SD; * skewed data as median (p25–p75)
RR blood pressure, LVEF left ventricular ejection fraction, GFR glomerular filtration rate, ERPF effective
renal plasma flow, RVR renovascular resistance, UAE urinary albumin excretion, NT-proBNP N-terminal
pro-brain natriuretic peptide, NGAL neutrophil gelatinase-associated lipocalin, KIM-1 kidney injury
molecule 1, NAG N-acetyl-b-D-glucosaminidase, ARB angiotensin receptor blocker, ACE angiotensin-
converting enzyme
** p\ 0.05 and # p\ 0.01 compared with patients with complete follow-up
Table 2 Association of
baseline markers with GFR
change (mL/min/1.73 m2) per
year corrected for baseline GFR,
age and sex
Variable Coef 95 % CI Beta p value
Age (years) -0.25 (-0.34 to -0.17) -0.64 \0.001
Female sex 2.7 (-0.31 to 5.75) 0.21 0.077
MAP (mmHg) -0.08 (-0.17 to 0.01) -0.22 0.064
LVEF (%) -0.08 (-0.21 to 0.04) -0.17 0.20
ERPF (mL/min/1.73 m2) 0.01 (-0.02 to 0.04) 0.17 0.54
RVR (mmHg/mL/min) -7.9 (-27 to 9.9) -0.15 0.38
Filtration fraction (%) -0.09 (-0.42 to 0.24) -0.06 0.61
NT-proBNP (ng/mL)* -0.29 (-0.98 to 0.40) -0.11 0.41
Hemoglobin (mmol/l) 0.15 (-1.6 to 1.9) -0.02 0.87
CRP (mg/L)* -0.17 (-0.93 to 0.60) -0.05 0.67
24 h Urine sodium (mmol) -4.6 (-14 to 4.8) -0.44 0.29
UAE (mg/24 h)* -0.19 (-0.79 to 0.41) -0.08 0.53
NGAL (lg/24 h)* -0.60 (-1.3 to 0.11) -0.21 0.096
KIM-1 (U/24 h)* -0.55 (-1.0 to -0.7) -0.27 0.027
NAG (ng/24 h)* -0.34 (-1.1 to 0.41) -0.11 0.36
GFR glomerular filtration rate, MAP mean arterial pressure, LVEF left ventricular ejection fraction, ERPF
effective renal plasma flow, RVR renovascular resistance, NT-proBNP N-terminal pro-brain natriuretic
peptide, CRP C-reactive protein, UAE urinary albumin excretion, NGAL neutrophil gelatinase-associated
lipocalin, KIM-1 kidney injury molecule 1, NAG N-acetyl-b-D-glucosaminidase
* log-transformed variables
Clin Res Cardiol (2016) 105:10–16 13
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failure [21–23] and chronic heart failure [24]. However, all
these studies used plasma creatinine to estimate GFR and
cannot differentiate between changes in hemodynamics
and kidney damage. In a previous analysis we demon-
strated a strong relation of renal blood flow with GFR in
HFREF patients [9].
In the current analysis, we found that none of the urinary
biomarkers or hemodynamic parameters at baseline could
predict renal function decline. Our study may have limited
power, because of the small change in GFR over time;
however, most of the aforementioned studies also demon-
strated a limited estimated GFR decline over time and by
using radioactive labeled tracers we can measure small
changes in GFR more accurately. We cannot exclude that
deceased subjects had a more rapid renal function decline.
These subjects did have a lower GFR and ERPF and higher
NT-proBNP at baseline; however, tubular damage markers
were not elevated in these subjects. What is most
remarkable is that they had a high RVR in combination
with a low filtration fraction and low blood pressure. This
may reflect the kidneys’ inability to maintain glomerular
perfusion pressure. They were more often on double renin–
angiotensin–aldosterone system (RAAS) blockers, which
may decrease the filtration fraction by vasodilation of the
efferent glomerular arteriole; however, this should cause a
decrease in RVR. The high RVR, therefore, must reflect a
different mechanism, possibly compromised kidney per-
fusion by increased venous pressure, sympathetic nerve
activation or a decreased amount of functioning glomeruli.
In our study, we found that the change in ERPF was the
strongest determinant of the change in GFR. In contrast, in
healthy individuals, GFR remains relatively stable with
moderate changes in renal blood flow [25]. It may be
speculated that impaired systemic circulation causes
decreased ERPF and, because of impaired intra-renal reg-
ulatory mechanisms, a parallel decline in GFR, but it may
also imply that both ERPF and GFR are affected by
intrarenal hemodynamic changes. Both congestion and
reduced cardiac output are thought to influence renal
function in heart failure patients. In our study, an increase
in NT-proBNP was associated with an increase in ERPF
and GFR. This is counterintuitive, since higher NT-
proBNP is associated with worsening cardiac function [26].
However, changes in volume status also influence NT-
proBNP levels, suggesting that not only congestion, but
also hypovolemia causes renal function decline in these
patients. Another explanation for the observed relationship
is that kidney damage affects both ERPF and GFR. How-
ever, many patients showed an increase in ERPF and an
associated increase in GFR, which suggests changes in
hemodynamics rather than in viable kidney tissue.
This study has several limitations. First, not all patients
were able to participate in the second measurement. The
deceased patients had worse baseline renal function, lower
blood pressure and higher NT-proBNP. Second, we only
had two measurements; therefore, we cannot establish if
there is a linear trend over time and cannot account for
fluctuations. Furthermore, our study has a modest sample
size. The measurements performed, however, are the gold
standard for measuring renal function, with a day-to-day
variation coefficient of less than 3 % for GFR and 5 % for
ERPF. Patients were mostly stable on medication; how-
ever, some patients had minor changes in dose or type of
Table 3 Associations between
hemodynamic changes and
changes in GFR
Coef 95 % CI Beta p value
Delta MAP (mmHg) -0.17 (-0.47 to 0.13) -0.14 0.25
Delta LVEF (%) 0.20 (-0.08 to 0.47) 0.16 0.16
Delta ERPF (mL/min/1.73 m2) 0.15 (0.11 to 0.19) 0.62 \0.001
Delta RVR (mmHg/mL/min) -110 (-172 to -47.9) -0.43 0.001
Delta log-NT-proBNP (ng/mL) 3.20 (1.17 to 5.22) 0.34 0.002
Models include age, sex and baseline values of the variable of interest
GFR glomerular filtration rate, MAP mean arterial pressure, LVEF left ventricular ejection fraction, ERPF
effective renal plasma flow, RVR renovascular resistance, NT-proBNP N-terminal pro-brain natriuretic
peptide
Fig. 2 Changes in GFR and ERPF
14 Clin Res Cardiol (2016) 105:10–16
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medication. Finally, this was a relatively young cohort,
with mostly male Caucasian patients.
Conclusion
In these stable chronic HFREF patients, long-term changes
in GFR were small, but strongly related to changes in
ERPF. None of the investigated urinary biomarkers and
hemodynamic parameters other than baseline GFR and age
could predict changes in GFR. This underlines the need for
the development of new renal risk markers and demon-
strates that changes in GFR are mostly driven by changes
in renal hemodynamics in chronic HFREF patients. Inter-
vention trials should investigate whether targeting ERPF
may improve GFR and reduce cardiac events and mortality.
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